Daratumumab is effective in the relapsed or refractory systemic light‐chain amyloidosis but associated with high infection burden in a frail real‐life population
Zoé Van de Wyngaert(Centre Hospitalier Universitaire de Lille), Eileen M. Boyle(BMW (Germany)), Isabelle Leduc(Centre Hospitalier d'Albi), Thierry Façon(Inserm), Paul Chauvet(Centre Hospitalier Universitaire de Lille), Laurent Pascal(Groupe Hospitalier de l'Institut Catholique de Lille), Alexandre Willaume(Hôpital Saint-Vincent-de-Paul), Salomon Manier(Centre National de la Recherche Scientifique), Benjamin Carpentier, Micha Srour, Charles Herbaux(Centre Hospitalier Universitaire de Lille), Jean‐Baptiste Gibier(Institut de Biologie de Lille), Louis Terriou, Pauline Lionne‐Huyghe(Centre Hospitalier d'Arras), Morgane Nudel(Centre Hospitalier Universitaire de Lille), Michèle Vasseur(Centre Hospitalier Universitaire de Lille), Sarah Barbieux(Centre Hospitalier Universitaire de Lille), Jean‐Baptiste Bossard(Centre Hospitalier Universitaire de Lille), Claire Bories(Guy's and St Thomas' NHS Foundation Trust), Hélène Demarquette
Cited by 29
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
|Nature Communications|2014|906
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
|Journal of Clinical Oncology|2015|564